Intelligence Report · ~12 min read

RK Pharma Intelligence Report

Generated from 2 signals · 2 evidence sources

Type

Company Intelligence Report

Generated

Aug 5, 2026

Confidence

Moderate Confidence · 72%

Evidence

12 items

Sources

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

RK Pharma maintains an active intelligence profile across Immunology, Immunosuppressant, Pulmonology, PAH. 2 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 72% across 2 tracked sources. Highest-priority development: FDA AP — SUGAMMADEX SODIUM (ORIG). Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for RK Pharma; the same agency is already in play for this signal, so precedent weight is higher.

Key Developments

Material intelligence events ranked by strategic relevance.

regulatory
FDA AP — SUGAMMADEX SODIUM (ORIG)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — SUGAMMADEX SODIUM (ORIG)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — SUGAMMADEX SODIUM (ORIG)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — MYCOPHENOLATE SODIUM (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — MYCOPHENOLATE SODIUM (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
Other | Cancer Accelerated Approvals
Regulatory precedent may inform portfolio positioning
View detail
regulatory
Rare Disease Drug Approvals
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA AP — SELEXIPAG (ORIG)
Regulatory precedent may inform portfolio positioning
View detail
regulatory
Verified Clinical Benefit | Cancer Accelerated Approvals
Regulatory precedent may inform portfolio positioning
View detail
regulatory
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Regulatory precedent may inform portfolio positioning
View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 46 with buyer quality 7 (Emerging). Competitive pressure: Low. Portfolio impact: High.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

FDA AP — SUGAMMADEX SODIUM (ORIG)
Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — SUGAMMADEX SODIUM (ORIG)
Moderate Confidence · 77%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — SUGAMMADEX SODIUM (ORIG)
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — MYCOPHENOLATE SODIUM (SUPPL)
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — MYCOPHENOLATE SODIUM (SUPPL)
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Other | Cancer Accelerated Approvals
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Rare Disease Drug Approvals
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA AP — SELEXIPAG (ORIG)
Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Verified Clinical Benefit | Cancer Accelerated Approvals
Moderate Confidence · 84%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Moderate Confidence · 84%
Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

FDA Grants Approval for Selexipag Application ANDA214055
Pulmonology · PAH
FDA Approval Status Update for Mycophenolate Sodium by RK Pharma
Immunology · Immunosuppressant

Executive Summary

Key Developments

FDA AP — SUGAMMADEX SODIUM (ORIG)

FDA AP — SUGAMMADEX SODIUM (ORIG)

FDA AP — SUGAMMADEX SODIUM (ORIG)

FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

Other | Cancer Accelerated Approvals

Rare Disease Drug Approvals

FDA AP — SELEXIPAG (ORIG)

Verified Clinical Benefit | Cancer Accelerated Approvals

FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

Strategic Implications

Supporting Evidence

FDA AP — SUGAMMADEX SODIUM (ORIG)

FDA AP — SUGAMMADEX SODIUM (ORIG)

FDA AP — SUGAMMADEX SODIUM (ORIG)

FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

FDA AP — MYCOPHENOLATE SODIUM (SUPPL)

Other | Cancer Accelerated Approvals

Rare Disease Drug Approvals

FDA AP — SELEXIPAG (ORIG)

Verified Clinical Benefit | Cancer Accelerated Approvals

FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

Related Intelligence

Signals